2020/10/19 by Barton F. Haynes, Lawrence Corey, Prabhavathi Fernandes +7 · 1 citation
Medicine · #COVID-19 Clinical Research Studies #COVID-19 Impact on Reproduction #Coronavirus #Coronavirus disease 2019 (COVID-19) #Disease #Immune system #Immunity #Immunology #Infectious disease (medical specialty) #Intensive care medicine #Internal medicine #Medicine #Pandemic #SARS-CoV-2 and COVID-19 Research #Vaccination #Virology
paper · doi:10.1126/scitranslmed.abe0948
openalex publication_date 2020/10/19 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/22
Rapid development of an efficacious vaccine against the viral pathogen severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the cause of the coronavirus disease 2019 (COVID-19) pandemic, is essential, but rigorous studies are required to determine the safety of candidate vaccines. Here, on behalf of the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Working Group, we evaluate research on the potential risk of immune enhancement of disease by vaccines and viral infections, including coronavirus infections, together with emerging data about COVID-19 disease. Vaccine-associated enhanced disease has been rarely encountered with existing vaccines or viral infections. Although animal models of SARS-CoV-2 infection may elucidate mechanisms of immune protection, we need observations of enhanced disease in people receiving candidate COVID-19 vaccines to understand the risk of immune enhancement of disease. Neither principles of immunity nor preclinical studies provide a basis for prioritizing among the COVID-19 vaccine candidates with respect to safety at this time. Rigorous clinical trial design and postlicensure surveillance should provide a reliable strategy to identify adverse events, including the potential for enhanced severity of COVID-19 disease, after vaccination.